JP3523033B2 - Prostate disease treatment - Google Patents

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a herbal medicine, "Large presentation".
(Common name: campylotropis trigonoclada [Franch.]
A. K. Schindl. (The above-mentioned ground part) of the present invention relates to a therapeutic agent for prostate diseases, which comprises an extract as an active ingredient.

[0002]

BACKGROUND OF THE INVENTION Prostatitis and proliferative hyperplasia are common diseases in middle-aged men. Incomplete statistics show that among men over 40 years old, the incidence of prostatitis and prostatic hyperplasia is over 40%. Prostatitis and prostatic hyperplasia always cause frequent urination, urinary speed, urinary pain, and urinary flow congestion, and give uncomfortable pain to patients. Up to now, several prostatic disease therapeutic agents manufactured by using Chinese herbs have been published. For example, CN10952 in Chinese Patent Publication
7A, injections disclosed in CN1134293A, CN1102102A, suppositories published in CN1121419A, CN1102330A, CN11
14581A, a skin external drug disclosed in CN1114582A and a Chinese herb formulation of Ganoderma lucidum disclosed in CN102103A.

[0003]

However, the above-mentioned therapeutic agents have drawbacks such as unclear therapeutic effects, large side effects, and inconvenient administration.

Since ancient times, the Chinese medicine "Large announcement" (common name: ca
mpylotropis trigonoclada [Franch. ] A. K. Schind
l. Is used for the treatment of enteritis, diarrhea, rheumatic pain, etc. ("Chinese Medicine Dictionary", page 1379). However, the Chinese herbal medicine "Large announcement" was not applied to the treatment of prostate disease.

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a therapeutic agent for prostate disease having a definite reducing effect on prostate disease.

[0006] Another object of the present invention is to provide a therapeutic agent for prostate disease containing a pharmacologically acceptable excipient.

[0007]

[Means for Solving the Problems] The inventors of the present invention have earnestly studied various kinds of traditional Chinese medicines in order to achieve the above-mentioned object, and as a result, the Chinese medicine "Large presentation" (common name: camp
ylotropis trigonoclada [Franch. ] A. K. Schind
l. It has been found that the above-mentioned extract) has a clear alleviating effect on prostatic diseases such as prostatitis and prostatic hyperplasia. The present invention has been completed based on the above findings.

The present invention resides in a therapeutic agent for prostate disease, which contains the extract of "Large presentation" as an active ingredient. In particular,
The "Large presentation" powder is an organic solvent that can be mixed with water, is heated to reflux at a constant temperature, and the insoluble matter is filtered from the extract,
It is a therapeutic agent for prostate diseases, which contains an extract powder obtained by spray-drying the extract obtained by distilling off the solvent from the filtrate under reduced pressure as an active ingredient.

The prophylactic disease therapeutic agent containing the "largely announced" extract according to the present invention will be described below. The conditions for the extraction of the active ingredients in the "Large presentation" are that the organic solvent that can be mixed with water is 30 to 80% ethanol or acetone solution, the heating reflux temperature is 40 to 85 ° C, and the extraction time is 1 It is preferably 3 hours. The extract is filtered and the relative density is 1.02 to 1.1 (45 to 50 ° C)
The solvent was distilled off under reduced pressure until the obtained extract was spray-dried,
Get the extract powder.

The present invention is also a therapeutic agent for prostate disease, which comprises the above extract powder as an active ingredient and a pharmacologically acceptable excipient. The above-mentioned excipients are mainly starch, microcrystalline cellulose, carboxymethyl cellulose and liquid paraffin. For the total amount of therapeutic agent,
The content of the extract powder and each excipient is 60 to 80% by weight of the extract powder, 10 to 30% by weight of starch, 5 to 20% by weight of microcrystalline cellulose, 1 to 5% by weight of carboxymethylcellulose, and 0.1 to 2 of liquid paraffin. % By weight.

As the dosage form of the therapeutic agent for prostate disease of the present invention, any dosage form such as granules, tablets and capsules can be adopted.

[0012]

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be specifically described with reference to Examples, but these do not limit the scope of the present invention in any way.

Production Example: Preparation of "Large Announcement" Extract Powder 1000 g of "Large Announcement" powder was heated under reflux with 50% ethanol for 2.5 hours, and the extract was filtered to give a relative density of 1.05 (42). The extract was spray-dried to obtain 56.8 g of extract powder.

Test Example 1: Reduction of prostate growth in mice by administration of the "large presentation" extract powder Body weight 32 ± 2 g ICR male mice (75 mice) were divided into 5 groups (15 mice in each group). Control group, testosterone propionate administration group (5 mg / kg.day), stilbestrol positive control group (0.5 mg / kg.day), respectively.
Sun), "Large presentation" extract powder low dose administration group (2 g / kg.
Sun), “Large announcement” extract powder high dose administration group (4 g / kg.
Day). In addition to the control group, each group is subcutaneously injected with testosterone propionate (5 mg / kg.day).
After 4 weeks, the prostate tissue was taken out from the animals, and the weight (Wet) of the leaf tissue was measured using an electronic Tenpyo (MetterAC-100). Proliferation was clearly suppressed.

Test Example 2: "Large presentation" The effect of lowering the prostate weight of rats by the administration of extract powder.

435 ± 56 g of SD aged rats (1.
(7 years) 58 animals were divided into 2 groups (29 animals in each group). These are the control group and the "Large presentation" extract powder administration group, respectively. Two
Administration is continued for 8 days. As a result of removing the prostate tissue from these animals and measuring the weight thereof, the prostate weight of the rat was remarkably reduced in the “large announcement” extract powder administration group.

Formulation Preparation Example 1: Preparation of Capsules 140 g of the "Large presentation" extract powder obtained in the above production example, 30 g of starch, 20 g of microcrystalline cellulose and 10 g of carboxymethyl cellulose were mixed and encapsulated in a gelatin capsule, 1000 capsules were prepared.

Formulation Preparation Example 2: Preparation of Granules 140 g of the "Large presentation" extract powder obtained in the above Production Example, 30 g of starch, 18 g of microcrystalline cellulose, 10 g of carboxymethyl cellulose and 2 g of liquid paraffin were uniformly mixed, 40 to 8 using a dry granulator
A No. 0 granule was prepared.

Formulation Preparation Example 3: Preparation of Tablets 70 g of the "Large presentation" extract powder obtained in the above Production Example, 15 g of starch, 10 g of microcrystalline cellulose and 5 g of carboxymethyl cellulose were mixed to prepare tablets according to a conventional method. (1000 tablets). (Weight per tablet 10
0 mg).

[0020]

As described above, the prophylactic disease therapeutic agent containing the extract of "Large presentation" according to the present invention as an active ingredient has a definite reducing effect on prostatic diseases such as prostatitis and proliferative hyperplasia. is there.

Although the present invention has been described above with reference to particular embodiments, it will be understood by those skilled in the art that modifications and variations are included in the scope of the present invention.

   ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Yang Xiao Yuan               China 650032 Kunming City, Yunnan Province                 Shiva Highway 51 Yunnan Baiyao               Industry Co., Ltd. (72) Inventor Chin Bai Pin               China 650032 Kunming City, Yunnan Province                 Shiva Highway 51 Yunnan Baiyao               Industry Co., Ltd. (72) Inventor Fan Yao               China 650032 Kunming City, Yunnan Province                 Shiva Highway 51 Yunnan Baiyao               Industry Co., Ltd. (72) Inventor Ron Fey               China 650032 Kunming City, Yunnan Province                 Shiva Highway 51 Yunnan Baiyao               Industry Co., Ltd.

Claims (8)

(57) [Claims] [Claim 1] "Large presentation" (common name: campylotropis trig
onoclada [Franch. ] A. K. Schindl. Above ground)
A therapeutic agent for prostate diseases, which comprises the extract of Escherichia coli as an active ingredient. 2. The extract of "Large presentation" is heated and refluxed at a constant temperature with an organic solvent capable of mixing the powder of "Large presentation" with water, insoluble matter is filtered from the extract, and the filtrate is extracted. The agent for treating prostate disease according to claim 1, which is an extract powder obtained by distilling off the solvent under reduced pressure and spray-drying the obtained extract. 3. The water-miscible organic solvent is a 30 to 80% ethanol or acetone solution, the heating reflux temperature is 40 to 85 ° C., the extraction time is 1-3 hours, and the extract relative density is 1. The therapeutic agent for prostate disease according to claim 2, wherein the solvent is distilled off under reduced pressure from 02 to 1.1 (45 to 50 ° C). 4. The therapeutic agent for prostate disease according to claim 1, which further comprises a pharmacologically acceptable excipient. 5. The therapeutic agent for prostate disease according to claim 4, wherein the excipients are mainly starch, microcrystalline cellulose, carboxymethyl cellulose and liquid paraffin. 6. An extract powder in an amount of 60 to 80% by weight, a starch in an amount of 10 to 30% by weight, a microcrystalline cellulose in an amount of 5 to 20% by weight, a carboxymethylcellulose in an amount of 1 to 5% by weight, and a flow amount based on the total amount of the therapeutic agent. The therapeutic agent for prostate diseases according to claim 5, which contains 0.5 to 1.5% by weight of paraffin. 7. Pharmaceutical capsules, granules or tablets
The agent for treating a prostatic disease according to any one of claims 1 to 6, which employs any of the dosage forms of. 8. The therapeutic agent for prostate disease according to claim 7, wherein the dosage form is a capsule, granule, or tablet.